Enveda Biosciences Secures $311 Million in Funding Round
AI drug discovery company Enveda Biosciences announced it has raised $311 million in a funding round. This information was initially reported by the company itself through press releases on Business Wire and BioSpace, and subsequently covered by outlets like qz.com, TradingView, and The Pharma Letter. The company stated the funding would be used to advance its AI-discovered natural medicines, with a focus on late-stage obesity and inflammatory disease research. The Pharma Letter specified this as a Series E round, while qz.com additionally reported that this funding round doubled Enveda's valuation to $2 billion.
9 articles from 8 outlets covered this story. No difference in framing or figures was found between them. The underlying claim is sourced from a press release.
What do all outlets agree on?
8 outlets covered “Enveda Biosciences Secures $311 Million in Funding Round”. All of them report the following:
- Enveda Biosciences raised $311 million
- The company uses AI for drug discovery
Did outlets disagree about this?
No. All 8 outlets covering “Enveda Biosciences Secures $311 Million in Funding Round” reported it the same way — no difference in framing or figures was found between them.
Which outlets covered this?
All 9 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.